Reduced angiogenesis in peritoneal dissemination of gastric cancer through gelatinase inhibition

Norihito Wada, Yoshihide Otani, Tetsuro Kubota, Masaru Kimata, Akiko Minagawa, Nobunari Yoshimizu, Kaori Kameyama, Yoshiro Saikawa, Masashi Yoshida, Toshiharu Furukawa, Masato Fujii, Koichiro Kumai, Yasunori Okada, Masaki Kitajima

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Marimastat is a broad-spectrum matrix metalloproteinase (MMP) inhibitor that inhibits almost all major MMPs, key enzymes in gastric cancer invasion and metastasis. We investigated the ability of marimastat to inhibit tumor angiogenesis in the severe combined immuno-deficient (SCID) mouse/human gastric cancer model of peritoneal dissemination. A human stomach adenocarcinoma cell line, TMK-1, was injected intraperitoneally into SCID mice. On the 7th day after tumor inoculation, the administration of marimastat (27 mg/kg/day) was initiated and the treatment was continued for 2 weeks using subcutaneously-inoculating mini-osmotic pumps. On the 21st day, the mice were killed and the disseminated nodules were evaluated. Total weights, numbers, and the microvascular density of the disseminating nodules were significantly lower in mice treated with marimastat compared to the control group. Film in situ zymography demonstrated that net gelatinolytic activity in the tissues was weaker in treated-group nodules than in control-group nodules. Thus, our results suggested that marimastat inhibited peritoneal dissemination of human gastric cancer cells through inhibition of tumor angiogenesis, possibly involving the down-regulation of gelatinases, in SCID mice injected with human gastric cancer cells.

Original languageEnglish
Pages (from-to)431-435
Number of pages5
JournalClinical and Experimental Metastasis
Volume20
Issue number5
DOIs
Publication statusPublished - 2003

Fingerprint

Gelatinases
Stomach Neoplasms
Neoplasms
Control Groups
Matrix Metalloproteinase Inhibitors
Matrix Metalloproteinases
Stomach
Adenocarcinoma
Down-Regulation
marimastat
Neoplasm Metastasis
Weights and Measures
Cell Line
Enzymes

Keywords

  • Film in situ zymography
  • Gastric neoplasm
  • Marimastat
  • Matrix metalloproteinase inhibitor
  • Microvascular density
  • Peritoneal metastasis
  • TMK-1

ASJC Scopus subject areas

  • Cancer Research

Cite this

Reduced angiogenesis in peritoneal dissemination of gastric cancer through gelatinase inhibition. / Wada, Norihito; Otani, Yoshihide; Kubota, Tetsuro; Kimata, Masaru; Minagawa, Akiko; Yoshimizu, Nobunari; Kameyama, Kaori; Saikawa, Yoshiro; Yoshida, Masashi; Furukawa, Toshiharu; Fujii, Masato; Kumai, Koichiro; Okada, Yasunori; Kitajima, Masaki.

In: Clinical and Experimental Metastasis, Vol. 20, No. 5, 2003, p. 431-435.

Research output: Contribution to journalArticle

Wada, N, Otani, Y, Kubota, T, Kimata, M, Minagawa, A, Yoshimizu, N, Kameyama, K, Saikawa, Y, Yoshida, M, Furukawa, T, Fujii, M, Kumai, K, Okada, Y & Kitajima, M 2003, 'Reduced angiogenesis in peritoneal dissemination of gastric cancer through gelatinase inhibition', Clinical and Experimental Metastasis, vol. 20, no. 5, pp. 431-435. https://doi.org/10.1023/A:1025453500148
Wada, Norihito ; Otani, Yoshihide ; Kubota, Tetsuro ; Kimata, Masaru ; Minagawa, Akiko ; Yoshimizu, Nobunari ; Kameyama, Kaori ; Saikawa, Yoshiro ; Yoshida, Masashi ; Furukawa, Toshiharu ; Fujii, Masato ; Kumai, Koichiro ; Okada, Yasunori ; Kitajima, Masaki. / Reduced angiogenesis in peritoneal dissemination of gastric cancer through gelatinase inhibition. In: Clinical and Experimental Metastasis. 2003 ; Vol. 20, No. 5. pp. 431-435.
@article{a2cd71c5cd6a4854b8b1beb09bd49e1e,
title = "Reduced angiogenesis in peritoneal dissemination of gastric cancer through gelatinase inhibition",
abstract = "Marimastat is a broad-spectrum matrix metalloproteinase (MMP) inhibitor that inhibits almost all major MMPs, key enzymes in gastric cancer invasion and metastasis. We investigated the ability of marimastat to inhibit tumor angiogenesis in the severe combined immuno-deficient (SCID) mouse/human gastric cancer model of peritoneal dissemination. A human stomach adenocarcinoma cell line, TMK-1, was injected intraperitoneally into SCID mice. On the 7th day after tumor inoculation, the administration of marimastat (27 mg/kg/day) was initiated and the treatment was continued for 2 weeks using subcutaneously-inoculating mini-osmotic pumps. On the 21st day, the mice were killed and the disseminated nodules were evaluated. Total weights, numbers, and the microvascular density of the disseminating nodules were significantly lower in mice treated with marimastat compared to the control group. Film in situ zymography demonstrated that net gelatinolytic activity in the tissues was weaker in treated-group nodules than in control-group nodules. Thus, our results suggested that marimastat inhibited peritoneal dissemination of human gastric cancer cells through inhibition of tumor angiogenesis, possibly involving the down-regulation of gelatinases, in SCID mice injected with human gastric cancer cells.",
keywords = "Film in situ zymography, Gastric neoplasm, Marimastat, Matrix metalloproteinase inhibitor, Microvascular density, Peritoneal metastasis, TMK-1",
author = "Norihito Wada and Yoshihide Otani and Tetsuro Kubota and Masaru Kimata and Akiko Minagawa and Nobunari Yoshimizu and Kaori Kameyama and Yoshiro Saikawa and Masashi Yoshida and Toshiharu Furukawa and Masato Fujii and Koichiro Kumai and Yasunori Okada and Masaki Kitajima",
year = "2003",
doi = "10.1023/A:1025453500148",
language = "English",
volume = "20",
pages = "431--435",
journal = "Clinical and Experimental Metastasis",
issn = "0262-0898",
publisher = "Springer Netherlands",
number = "5",

}

TY - JOUR

T1 - Reduced angiogenesis in peritoneal dissemination of gastric cancer through gelatinase inhibition

AU - Wada, Norihito

AU - Otani, Yoshihide

AU - Kubota, Tetsuro

AU - Kimata, Masaru

AU - Minagawa, Akiko

AU - Yoshimizu, Nobunari

AU - Kameyama, Kaori

AU - Saikawa, Yoshiro

AU - Yoshida, Masashi

AU - Furukawa, Toshiharu

AU - Fujii, Masato

AU - Kumai, Koichiro

AU - Okada, Yasunori

AU - Kitajima, Masaki

PY - 2003

Y1 - 2003

N2 - Marimastat is a broad-spectrum matrix metalloproteinase (MMP) inhibitor that inhibits almost all major MMPs, key enzymes in gastric cancer invasion and metastasis. We investigated the ability of marimastat to inhibit tumor angiogenesis in the severe combined immuno-deficient (SCID) mouse/human gastric cancer model of peritoneal dissemination. A human stomach adenocarcinoma cell line, TMK-1, was injected intraperitoneally into SCID mice. On the 7th day after tumor inoculation, the administration of marimastat (27 mg/kg/day) was initiated and the treatment was continued for 2 weeks using subcutaneously-inoculating mini-osmotic pumps. On the 21st day, the mice were killed and the disseminated nodules were evaluated. Total weights, numbers, and the microvascular density of the disseminating nodules were significantly lower in mice treated with marimastat compared to the control group. Film in situ zymography demonstrated that net gelatinolytic activity in the tissues was weaker in treated-group nodules than in control-group nodules. Thus, our results suggested that marimastat inhibited peritoneal dissemination of human gastric cancer cells through inhibition of tumor angiogenesis, possibly involving the down-regulation of gelatinases, in SCID mice injected with human gastric cancer cells.

AB - Marimastat is a broad-spectrum matrix metalloproteinase (MMP) inhibitor that inhibits almost all major MMPs, key enzymes in gastric cancer invasion and metastasis. We investigated the ability of marimastat to inhibit tumor angiogenesis in the severe combined immuno-deficient (SCID) mouse/human gastric cancer model of peritoneal dissemination. A human stomach adenocarcinoma cell line, TMK-1, was injected intraperitoneally into SCID mice. On the 7th day after tumor inoculation, the administration of marimastat (27 mg/kg/day) was initiated and the treatment was continued for 2 weeks using subcutaneously-inoculating mini-osmotic pumps. On the 21st day, the mice were killed and the disseminated nodules were evaluated. Total weights, numbers, and the microvascular density of the disseminating nodules were significantly lower in mice treated with marimastat compared to the control group. Film in situ zymography demonstrated that net gelatinolytic activity in the tissues was weaker in treated-group nodules than in control-group nodules. Thus, our results suggested that marimastat inhibited peritoneal dissemination of human gastric cancer cells through inhibition of tumor angiogenesis, possibly involving the down-regulation of gelatinases, in SCID mice injected with human gastric cancer cells.

KW - Film in situ zymography

KW - Gastric neoplasm

KW - Marimastat

KW - Matrix metalloproteinase inhibitor

KW - Microvascular density

KW - Peritoneal metastasis

KW - TMK-1

UR - http://www.scopus.com/inward/record.url?scp=0041736273&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0041736273&partnerID=8YFLogxK

U2 - 10.1023/A:1025453500148

DO - 10.1023/A:1025453500148

M3 - Article

C2 - 14524532

AN - SCOPUS:0041736273

VL - 20

SP - 431

EP - 435

JO - Clinical and Experimental Metastasis

JF - Clinical and Experimental Metastasis

SN - 0262-0898

IS - 5

ER -